Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2010, Article ID 686480, 4 pages
http://dx.doi.org/10.1155/2010/686480
Review Article

Efficacy and Cytokine Modulating Effects of Tacrolimus in Systemic Lupus Erythematosus: A Review

El Shaddai Arthritis and Rheumatism Specialist Medical Centre, Block 102, #01-258, Towner Road, Singapore 322102

Received 27 February 2010; Accepted 31 March 2010

Academic Editor: Brian Poole

Copyright © 2010 Kam Hon Yoon. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. S. Lau, “Who's afraid of the big bad wolf? Fifth Tay Chong Hai lecture of the national arthritis foundation of Singapore,” APLAR Journal of Rheumatology, vol. 7, no. 1, pp. 83–89, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. D. A. De Albuquerque, F. M. Ebling, D. W. Lienesch, R. R. Singh, and B. H. Hahn, “Analyses of serum levels of type 1, type 2 and type 3 cytokines reveal multiple abnormalities in lupus-prone (NZB × NZW) F1 mice,” APLAR Journal of Rheumatology, vol. 7, no. 1, pp. 3–10, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. G. Grondal, I. Gunnarsson, J. Ronnelid, S. Rogberg, L. Klareskog, and I. Lundberg, “Cytokine production, serum levels and disease activity in systemic lupus erythematosus,” Clinical and Experimental Rheumatology, vol. 18, no. 5, pp. 565–570, 2000. View at Google Scholar · View at Scopus
  4. K. Takabayashi, T. Koike, K. Kurasawa et al., “Effect of FK-506, a novel immunosuppressive drug on murine systemic lupus erythematosus,” Clinical Immunology and Immunopathology, vol. 51, no. 1, pp. 110–117, 1989. View at Google Scholar · View at Scopus
  5. C. Entani, Y. Izumino, H. Iida et al., “Effect of a novel immunosuppressant, FK506, on spontaneous lupus nephritis in MRL/MpJ-lpr/lpr mice,” Nephron, vol. 64, no. 3, pp. 471–475, 1993. View at Google Scholar · View at Scopus
  6. M. Duddridge and R. J. Powell, “Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus: a report of three cases,” Annals of the Rheumatic Diseases, vol. 56, no. 11, pp. 690–692, 1997. View at Google Scholar · View at Scopus
  7. S. L. Walker, B. Kirby, and R. J. G. Chalmers, “The effect of topical tacrolimus on severe recalcitrant chronic discoid lupus erythematosus,” British Journal of Dermatology, vol. 147, no. 2, pp. 405–406, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Kanekura, N. Yoshii, K. Terasaki, H. Miyoshi, and T. Kanzaki, “Efficacy of topical tacrolimus for treating the malar rash of systemic lupus erythematosus,” British Journal of Dermatology, vol. 148, no. 2, pp. 353–356, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. V. Madan, P. J. August, and R. J. Chalmers, “Efficacy of topical tacolimus 0.3% in clobetasol propionate 0.05% ointment in therapy-resistant cutaneous lupus erythematosus: a cohort study,” Clinical and Experimental Dermatology, vol. 35, no. 1, pp. 27–30, 2010. View at Google Scholar
  10. K. Yoshie, T. Nahoko, K. Kaichi et al., “Tacrolimus therapy for systemic lupus erythematosus without renal involvement: a preliminary retrospective study,” Modern Rheumatology, vol. 19, no. 6, pp. 329–333, 2009. View at Google Scholar
  11. K. H. Yoon, “Successful usage of tacrolimus (FK506) in resistant/relapsed rheumatic diseases,” APLAR Journal of Rheumatology, vol. 7, no. 1, pp. 44–48, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. C. L. Suzanne, K. Yukiko, L. Kenneth et al., “Treatment of pediatric patients with severe systemic lupus erythematosus with tacrolimus,” Annals of Rheumatic Diseases, supplement, pp. 48–49, 2003. View at Google Scholar
  13. C. C. Mok, K. H. Tong, C. H. To, Y. P. Siu, and T. C. Au, “Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study,” Kidney International, vol. 68, no. 2, pp. 813–817, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. H. T. Zhang, W. X. Hu, H. L. Xie et al., “Tacrolimus versus intravenous cyclophosphamide in the induction therapy of diffuse proliferative lupus nephritis,” Nephrology Dialysis Transplantation, vol. 15, pp. 501–507, 2006. View at Google Scholar
  15. M. Maruyama, Y. Yamasaki, K. Sada et al., “Good response of membranous lupus nephritis to tacrolimus,” Clinical Nephrology, vol. 65, no. 4, pp. 276–279, 2006. View at Google Scholar · View at Scopus
  16. C.-C. Szeto, B. C.-H. Kwan, F. M.-M. Lai et al., “Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis,” Rheumatology, vol. 47, no. 11, pp. 1678–1681, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. K. C. Tse, M. F. Lam, S. C. W. Tang, C. S. O. Tang, and T. M. Chan, “A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade,” Lupus, vol. 16, no. 1, pp. 46–51, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Yukari, U. Keiko, O. Shigeru et al., “Clinical assessment of tacrolimus therapy in lupus nephritis: one-year follow-up study in a single center,” Nephron Clinical Practice, vol. 113, pp. 330–336, 2009. View at Google Scholar
  19. M. Nobuyuki, K. Shinichi, and H. Hiroshi, “Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study,” Modern Rheumatology, vol. 19, no. 6, pp. 606–615, 2009. View at Google Scholar
  20. H. Bao, Z. H. Liu, H.-L. Xie, W.-X. Hu, H.-T. Zhang, and L.-S. Li, “Successful treatment of class V+IV lupus nephritis with multitarget therapy,” Journal of the American Society of Nephrology, vol. 19, no. 10, pp. 2001–2010, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. H. T. Zhang, W. X. Hu, H. L. Xie et al., “Randomized controlled trial of tacrolimus versus intravenous cyclophosphamide in the induction therapy of class V plus IV lupus nephritis,” Nephrology Dialysis Transplantation, vol. 15, pp. 508–514, 2006. View at Google Scholar
  22. K. S. Peterson and R. Winchester, “Systemic lupus erythematosus,” in Pathogenesis, J. K. William and W. M. Larry, Eds., pp. 1523–1559, Lippincott Williams & Wilikins, Philadelphia, Pa, USA, 2005. View at Google Scholar
  23. K. A. Kirou and M. K. Crow, “New pieces to the SLE cytokine puzzle,” Clinical Immunology, vol. 91, no. 1, pp. 1–5, 1999. View at Google Scholar · View at Scopus
  24. L. C. Ginus, A. B. Cosim, and P. J. Morris, Transplantation, Blackwell Science, Oxford, UK, 1999.
  25. S. Sakuma, Y. Kato, F. Nishigaki et al., “FK506 potently inhibits T cell activation induced TNF-a and IL-1ß production in vitro by human peripheral blood mononuclear cells,” British Journal of Pharmacology, vol. 130, no. 7, pp. 1655–1663, 2000. View at Google Scholar · View at Scopus
  26. S. Sakuma, Y. Higashi, N. Sato et al., “Tacrolimus suppressed the production of cytokines involved in atopic dermatitis by direct stimulation of human PBMC system. (Comparison with steroids),” International Immunopharmacology, vol. 1, no. 6, pp. 1219–1226, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Magari, S. Miyata, F. Nishigaki, Y. Ohkubo, S. Mutoh, and T. Goto, “Differential effects of FK506 and methotrexate on inflammatory cytokine levels in rat adjuvant-induced arthritis,” Journal of Rheumatology, vol. 30, no. 10, pp. 2193–2200, 2003. View at Google Scholar · View at Scopus
  28. S. Sakuma, Y. Kato, F. Nishigaki et al., “Effects of FK506 and other immunosuppressive anti-rheumatic agents on T cell activation mediated IL-6 and IgM production in vitro,” International Immunopharmacology, vol. 1, no. 4, pp. 749–757, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. Y. Furukawa, H. Yoshikawa, K. Iwasa, and M. Yamada, “Clinical efficacy and cytokine network-modulating effects of tacrolimus in myasthenia gravis,” Journal of Neuroimmunology, vol. 195, no. 1-2, pp. 108–115, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Sugiyama, M. Funauchi, T. Yamagata et al., “Predominant inhibition of Th1 cytokines in New Zealand black/white F1 mice treated with FK506,” Scandinavian Journal of Rheumatology, vol. 33, no. 2, pp. 108–114, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Jiang, C. Wynn, F. Pan, A. Ebbs, L. M. Erickson, and M. Kobayashi, “Tacrolimus and cyclosporine differ in their capacity to overcome ongoing allograft rejection as a result of their differential abilities to inhibit interleukin-10 production,” Transplantation, vol. 73, no. 11, pp. 1808–1817, 2002. View at Google Scholar · View at Scopus
  32. L. Llorente and Y. Richaud-Patin, “The role of interleukin-10 in systemic lupus erythematosus,” Journal of Autoimmunity, vol. 20, no. 4, pp. 287–289, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Heidt, D. L. Roelen, C. Eijsink et al., “Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help,” The Journal of Translational Immunology, vol. 159, no. 2, pp. 199–207, 2009. View at Google Scholar
  34. P. Blanco, V. Pitard, J.-F. Viallard, J.-L. Taupin, J.-L. Pellegrin, and J.-F. Moreau, “Increase in activated CD8+ T lymphocytes expressing perforin and granzyme B correlates with disease activity in patients with systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 52, no. 1, pp. 201–211, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. L. Couzi, P. Merville, C. Deminiere et al., “Predominance of CD8+ T lymphocytes among periglomerular infiltrating cells and link to the prognosis of class III and class IV lupus nephritis,” Arthritis and Rheumatism, vol. 56, no. 7, pp. 2362–2370, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. R. J. Glassock, “Multitarget therapy of lupus nephritis: base hit or home run?” Journal of the American Society of Nephrology, vol. 19, no. 10, pp. 1842–1844, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. O. Millan, M. Brunet, J. M. Campistol et al., “Pharmacodynamic approach to immunosuppressive therapies using calcineurin inhibitors and mycophenolate mofetil,” Clinical Chemistry, vol. 49, no. 11, pp. 1891–1899, 2003. View at Publisher · View at Google Scholar · View at Scopus